These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6184099)

  • 41. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
    Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
    Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
    Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
    Dryzhak VI
    Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239
    [No Abstract]   [Full Text] [Related]  

  • 47. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
    Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
    Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
    Massner B; Voss I; Queisser W; Drings P; Fritze D; Westerhausen M
    Onkologie; 1982 Aug; 5 Suppl():46-51. PubMed ID: 6752791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
    Lindberg H; Nielsen DL; Tuxen M; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3096-100. PubMed ID: 17877958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment.
    Harris EE; Christensen VJ; Hwang WT; Fox K; Solin LJ
    J Clin Oncol; 2005 Jan; 23(1):11-6. PubMed ID: 15545665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.
    Chlebowski RT; Irwin LE; Pugh RP; Sadoff L; Hestorff R; Wiener JM; Bateman JR
    Cancer Res; 1979 Nov; 39(11):4503-6. PubMed ID: 387216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endocrine treatment of breast cancer.
    Ravdin PM
    Curr Ther Endocrinol Metab; 1994; 5():556-62. PubMed ID: 7704791
    [No Abstract]   [Full Text] [Related]  

  • 54. [Role of chemotherapy in the treatment of bone metastases of breast cancer].
    Cayla J; Auclerc C; Goldberg D; Darne C; Jacquillat C
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):651-6. PubMed ID: 6523016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial.
    Wada T; Koyama H; Terasawa T
    Breast Cancer Res Treat; 1981; 1(1):53-8. PubMed ID: 6816315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic regimens in advanced breast cancer.
    Hoge AF; Shaw MT; Bottomley RH; Hartsuck JM
    JAMA; 1975 Mar; 231(13):1357-60. PubMed ID: 1173080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
    Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
    Cancer; 1979 Apr; 43(4):1225-33. PubMed ID: 445325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
    Brufman G; Biran S
    Acta Oncol; 1990; 29(6):717-20. PubMed ID: 2223141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.